简
/
繁
/
EN
About Us
R&D
Products
News
Careers
Investors
Contact us
Investors
（02186.HK）
HK$
➚
%
Volume(M)
0thousand
Turnover(HK $)
0thousand
Data as of：
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Year
2022
2023
2024
2025
29
2025-04
FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING TO BE HELD ON 5 JUNE 2025 (APPLICABLE TO HOLDERS OF H SHARES)
29
2025-04
NOTICE OF ANNUAL GENERAL MEETING
29
2025-04
(1) 2024 REPORT OF THE BOARD OF DIRECTORS (2) 2024 REPORT OF THE BOARD OF SUPERVISORS (3) 2024 ANNUAL REPORT (4) PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR (5) PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR (6) RE-APPOINTMENT OF AUDITOR (7) REMUNERATION O
29
2025-04
2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
29
2025-04
ANNUAL REPORT 2024
29
2025-04
PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
02
2025-04
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2025
27
2025-03
PROPOSED APPOINTMENTS OF EXECUTIVE DIRECTOR AND NON-EXECUTIVE DIRECTOR
27
2025-03
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024
26
2025-03
BA1302 GRANTED ODD FOR SQNSCLC AND PANCREATIC CANCER BY U.S. FDA
1
2
3
4
5
Follow me
鲁公网安备37069102000284